 VANCOUVER, Jan. 27, 2021 GLOBE NEWSWIRE -- BetterLife Pharma Inc. BetterLife or the Company CSE: BETR OTCQB: BETRF FRA: NPAU , an emerging biotech company focused on the development and commercialization of cutting-edge treatments in mental disorders and viral infections, announces it has entered into an agreement with Eurofins Discovery for TD-0148As U.S. FDA Investigational New Drug IND-enabling pharmacology studies. TD-0148A is a second-generation Lysergic Acid Diethylamide LSD derivative molecule that BetterLife believes will mimic the projected therapeutic potential of LSD without causing the undesirable psychoactive dissociative side effects, such as hallucinations. 